• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Biodesix Inc. (Amendment)

    8/11/23 4:31:35 PM ET
    $BDSX
    Medical Specialities
    Health Care
    Get the next $BDSX alert in real time by email
    SC 13D/A 1 brhc20057429_sc13da.htm SC 13D/A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13D
    Under the Securities Exchange Act of 1934
    (Amendment No. 4)*

    Biodesix, Inc.
    (Name of Issuer)

    Common Stock, Par Value $0.001 Per Share
    (Title of Class of Securities)

    09075X108
    (CUSIP Number)

    Jack W. Schuler
    100 N. Field Drive, Suite 360
    Lake Forest, Illinois 60045
    (224) 880-1210
    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

    August 3, 2023
    (Date of Event which Requires Filing of this Statement)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    CUSIP No: 09075X108
    SCHEDULE 13D
    Page 2 of 6 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    Jack W. Schuler
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    PF
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    208,362 (1)
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    30,579,359
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    208,362 (1)
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    30,579,359
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    30,787,721 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    32.1% (2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     

    1.
    This amount includes 208,362 Shares (as defined herein) that the Reporting Person has the right to acquire within 60 days of the date of this filing.

    2.
    This percentage is based on a total of 78,614,114 Shares outstanding as of August 1, 2023, as reported in the Issuer’s quarterly report on Form 10-Q filed on August 7, 2023, plus the aggregate 16,975,298 Shares to be issued in the PIPE (as defined herein), and 208,362 Shares that the Reporting Person has the right to acquire within 60 days of the date of this filing.


    CUSIP No: 09075X108
    SCHEDULE 13D
    Page 3 of 6 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    Jack W. Schuler Living Trust
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    WC
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Illinois
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    30,579,359
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    30,579,359
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    30,579,359
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    32.0% (1)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    1.
    This percentage is based on a total of 78,614,114 Shares outstanding as of August 1, 2023, as reported in the Issuer’s quarterly report on Form 10-Q filed on August 7, 2023, plus the aggregate 16,975,298 Shares to be issued in the PIPE.


    CUSIP No: 09075X108
    SCHEDULE 13D
    Page 4 of 6 Pages
    Item 1.
    Security and Issuer

    Item 1 of the Schedule 13D is hereby amended and supplemented as follows:

    This Amendment No. 4 to Schedule 13D (“Amendment No. 4”) is being filed by the undersigned, pursuant to §240.13d-2(a), to amend and supplement the Schedule 13D filed with the U.S. Securities and Exchange Commission (the “SEC”) on November 9, 2020, (the “Initial Schedule 13D”), as amended on January 28, 2022, on April 11, 2022, and on November 23, 2022 (collectively, the “Schedule 13D”), with respect to the common stock, par value $0.001 per share (the “Shares”), of Biodesix, Inc. (the “Issuer” or the “Company”), whose principal executive offices are located at 2970 Wilderness Place, Suite 100, Boulder, Colorado 80301.

    Item 3.
    Source and Amount of Funds or Other Consideration

    Item 3 of the Schedule 13D is hereby amended and supplemented as follows:

    On August 3, 2023, the Issuer entered into subscription agreements (the “Subscription Agreements”) with certain shareholders of the Issuer, including the Trust, and management (the “Subscribers”), pursuant to which the Subscribers agreed to subscribe for and purchase, and the Issuer agreed to issue and sell to the Subscribers, an aggregate of 16,975,298 Shares in a private equity offering, at a purchase price of $1.62 per Share, for an aggregate purchase price of approximately $27.5 million (the “PIPE”). Pursuant to the Subscription Agreements, funding will occur in two separate tranches on August 31, 2023 and September 29, 2023. The Subscription Agreements include customary representations, warranties and covenants by the parties to the Subscription Agreements. The Subscription Agreements do not include any registration rights.

    The Trust purchased 9,989,506 Shares in the PIPE, at a purchase price of $1.62 per Share, for an aggregate purchase price of approximately $16,183,000, using Mr. Schuler’s personal funds.

    The foregoing description of the Subscription Agreements does not purport to be complete and is qualified in its entirety by reference to the full text of the Subscription Agreements, the form of which is attached as Exhibit 4 to this Amendment No. 4 and is incorporated herein by reference.

    Item 4.
    Purpose of Transaction

    Item 4 of the Schedule 13D is hereby amended and supplemented as follows:

    The response to Item 3 of this Amendment No. 4 is incorporated by reference herein.

    Item 5.
    Interest in Securities of the Issuer

    Item 5(a) - (c) of the Schedule 13D is hereby amended and supplemented as follows:

    (a, b) As of the date hereof, Mr. Schuler may be deemed to beneficially own, in the aggregate, 30,787,721 Shares, which represents approximately 32.1% of the Shares outstanding.

    Mr. Schuler’s beneficial ownership consists of (1) 46,102 Shares that Mr. Schuler has the right to acquire upon exercise of options exercisable within 60 days of the date of this filing, (2) 162,260 Shares that Mr. Schuler has the right to acquire upon vesting of RSUs within 60 days of the date of this filing, and (3) 30,579,359 Shares held by the Trust, representing approximately 32.0% of the Shares outstanding.

    The foregoing beneficial ownership percentages are based on a total of 78,614,114 Shares outstanding as of August 1, 2023, as reported in the Issuer’s quarterly report on Form 10-Q filed on August 7, 2023, plus the aggregate 16,975,298 Shares to be issued in the PIPE, and, for purposes of calculating Mr. Schuler’s beneficial ownership percentage, 208,362 Shares that Mr. Schuler has the right to acquire within 60 days of the date of this filing.

    As sole trustee of the Trust, Mr. Schuler shares with the Trust the power to vote or direct the vote, and the power to dispose or direct the disposition of, the 30,579,359 Shares beneficially owned by the Trust.


    CUSIP No: 09075X108
    SCHEDULE 13D
    Page 5 of 6 Pages
    (c) The response to Item 3 of this Amendment No. 4 is incorporated by reference herein. Except as set forth in this Amendment No. 4, no transactions in the Shares have been effected by the Reporting Person within the past 60 days.

    Item 6.
    Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

    Item 6 of the Schedule 13D is hereby amended and supplemented as follows:

    The response to Item 3 of this Amendment No. 4 is incorporated by reference herein.

    Except as otherwise set forth in this Amendment No. 4, there are no contracts, arrangements, understandings or relationships between the Reporting Persons and any other person with respect to any securities of the Issuer.

    Item 7.
    Material to be Filed as Exhibits

    Item 7 of the Schedule 13D is hereby amended and supplemented as follows:

    Exhibit 4
    Form of Subscription Agreement (incorporated by reference to Exhibit 10.1 to the Issuer’s quarterly report on Form 10-Q filed with the SEC on August 7, 2023).


    CUSIP No: 09075X108
    SCHEDULE 13D
    Page 6 of 6 Pages
    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Jack W. Schuler
     
    /s/ Jack W. Schuler
       
     
    Jack W. Schuler Living Trust
     
    /s/ Jack W. Schuler
     
    Name: Jack W. Schuler
     
    Title: Trustee
       
    August 11, 2023
     

    Attention: Intentional misstatements or omissions of fact constitute federal violations (see 18 U.S.C. 1001).



    Get the next $BDSX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BDSX

    DatePrice TargetRatingAnalyst
    5/14/2025Outperform → Mkt Perform
    William Blair
    9/16/2024Sector Outperform
    Scotiabank
    7/26/2024$3.00Buy
    Craig Hallum
    5/13/2024$2.80Buy
    TD Cowen
    5/3/2024$3.00Buy
    Lake Street
    11/17/2021$21.00 → $11.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $BDSX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Biodesix downgraded by William Blair

    William Blair downgraded Biodesix from Outperform to Mkt Perform

    5/14/25 8:54:25 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Scotiabank initiated coverage on Biodesix

    Scotiabank initiated coverage of Biodesix with a rating of Sector Outperform

    9/16/24 8:45:16 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Craig Hallum initiated coverage on Biodesix with a new price target

    Craig Hallum initiated coverage of Biodesix with a rating of Buy and set a new price target of $3.00

    7/26/24 7:48:11 AM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Emeritus Director Schuler Jack W bought $1,180,736 worth of shares (100,000 units at $11.81) (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    1/27/26 9:29:02 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Emeritus Director Schuler Jack W bought $903,561 worth of shares (82,465 units at $10.96) (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    1/26/26 9:28:57 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Chief Accounting Officer Vazquez Chris converted options into 219 shares and sold $676 worth of shares (83 units at $8.15), increasing direct ownership by 15% to 1,072 units (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    1/20/26 4:22:18 PM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    SEC Filings

    View All

    SEC Form S-8 filed by Biodesix Inc.

    S-8 - BIODESIX INC (0001439725) (Filer)

    2/6/26 4:14:20 PM ET
    $BDSX
    Medical Specialities
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Biodesix Inc.

    SCHEDULE 13D/A - BIODESIX INC (0001439725) (Subject)

    1/27/26 2:28:12 PM ET
    $BDSX
    Medical Specialities
    Health Care

    SEC Form SCHEDULE 13G filed by Biodesix Inc.

    SCHEDULE 13G - BIODESIX INC (0001439725) (Subject)

    1/26/26 1:59:41 PM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $BDSX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited)

    Estimated Q4 2025 Revenue of $28.8 million, an increase of 41%; Grew full-year revenue to an estimated $88.5 million, an increase of 24%; Affirms guidance of Adjusted EBITDA positivity in Q4 2025. LOUISVILLE, Colo., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX) (the company), a leading diagnostic solutions company, today announced its preliminary financial results for the fourth quarter and year ended December 31, 2025 (fiscal 2025). The financial results included in this release pertaining to the fourth quarter and fiscal 2025 are preliminary, unaudited, and subject to final review and adjustment. "Biodesix finished 2025 with a strong fourth quarter delivering

    1/12/26 6:00:00 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Biodesix to Present New Data at Two Major Upcoming Scientific Meetings

    Clinical utility data for Nodify Lung® tests to be presented at North American Conference on Lung Cancer (NACLC) highlighting potential for earlier diagnosis of lung cancer Development data for a new ultra-sensitive ESR1 assay for breast cancer treatment resistance monitoring to be presented at San Antonio Breast Cancer Symposium (SABCS) LOUISVILLE, Ky., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostics solutions company, announces several poster presentations on lung cancer diagnostics and new research on breast cancer diagnostics at upcoming scientific meetings. At the 2025 North American Conference on Lung Cancer (NACLC), December 5 - 7, in Chicago

    12/3/25 8:22:00 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Biodesix Announces Third Quarter 2025 Results and Highlights

    Q3 2025 Revenue of $21.8 million, an increase of 20% over Q3 2024; Q3 2025 gross profit margin of 81%, a 400-basis point improvement from Q3 2024; Raised FY2025 Total Revenue Guidance to $84-86 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the third quarter ended September 30, 2025. "We delivered a strong third quarter with revenue growing 20% to $21.8 million and continued to improve our already strong gross margins to 81%, a 400-basis point increase year-over-year," said Scott Hutton, Chief Exe

    11/3/25 4:01:00 PM ET
    $BDSX
    Medical Specialities
    Health Care

    Emeritus Director Schuler Jack W bought $1,180,736 worth of shares (100,000 units at $11.81) (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    1/27/26 9:29:02 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Emeritus Director Schuler Jack W bought $903,561 worth of shares (82,465 units at $10.96) (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    1/26/26 9:28:57 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Director Schuler Jack W bought $999,997 worth of shares (142,045 units at $7.04) (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    9/23/25 9:29:04 AM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    Financials

    Live finance-specific insights

    View All

    Biodesix Announces Third Quarter 2025 Results and Highlights

    Q3 2025 Revenue of $21.8 million, an increase of 20% over Q3 2024; Q3 2025 gross profit margin of 81%, a 400-basis point improvement from Q3 2024; Raised FY2025 Total Revenue Guidance to $84-86 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the third quarter ended September 30, 2025. "We delivered a strong third quarter with revenue growing 20% to $21.8 million and continued to improve our already strong gross margins to 81%, a 400-basis point increase year-over-year," said Scott Hutton, Chief Exe

    11/3/25 4:01:00 PM ET
    $BDSX
    Medical Specialities
    Health Care

    Biodesix to Report Third Quarter 2025 Financial Results on November 3, 2025

    LOUISVILLE, Colo., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the third quarter ended September 30, 2025 after the close of trading on Monday, November 3. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Listeners can register for the webcast via this link. Analysts who wish to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours aft

    10/20/25 6:00:00 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Biodesix Announces One-for-Twenty Reverse Stock Split

    LOUISVILLE, Colo., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX) ("Biodesix" or the "Company"), a leader in personalized diagnostics, today announced a one-for-twenty reverse stock split (the "Reverse Stock Split") of the Company's common stock, par value $0.001, which will become effective at 12:01 a.m. Eastern Time on Monday, September 15, 2025. The Company's common stock will continue to trade under Biodesix's existing trading symbol, BDSX, on the Nasdaq Global Market ("Nasdaq") on a split-adjusted basis when the market opens on Monday, September 15, 2025, with the new CUSIP number 09075X207. The Reverse Stock Split was approved by Biodesix's stockholders at the a

    9/11/25 8:00:00 AM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    Leadership Updates

    Live Leadership Updates

    View All

    Biodesix Announces Appointment of Lawrence (Lair) T. Kennedy, Jr. to Board of Directors

    Biodesix, Inc. (NASDAQ:BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the appointment of Lawrence (Lair) T. Kennedy, Jr. to the Company's Board of Directors (Board) and Audit Committee of the Board effective January 3, 2023. Mr. Kennedy brings to Biodesix more than 20 years of broad operating, corporate finance, company creation and investment experience with a specific focus in the healthcare industry. "We are delighted to welcome Lair to Biodesix's Board of Directors," said Scott Hutton, Chief Executive Officer of Biodesix. "He brings a wealth of business experience with a strong background in healthcare and diagnostics. We look fo

    12/16/22 4:01:00 PM ET
    $BDSX
    Medical Specialities
    Health Care

    Biodesix Announces Appointment of Successful Innovator and Scientific Professional Jon Faiz Kayyem, PhD to Board of Directors

    Biodesix, Inc. (NASDAQ:BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced the appointment of Dr. Jon Faiz Kayyem to the company's board of directors. Dr. Kayyem's diverse career spans more than 20 years and includes experience in academia, lean startups, and Fortune 100 companies. He has served in various leadership positions throughout his career including numerous roles at GenMark Diagnostics, including Founder, CEO and President, Chief Scientific Officer, Senior Vice President of Research and Development. Prior to his work at GenMark Diagnostics, Dr. Kayyem served as Director and Founder of Calimmune and was Vice President of Life Sciences a

    12/8/21 6:00:00 AM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biodesix Inc.

    SC 13G/A - BIODESIX INC (0001439725) (Subject)

    11/13/24 7:30:22 AM ET
    $BDSX
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Biodesix Inc.

    SC 13G - BIODESIX INC (0001439725) (Subject)

    6/24/24 12:16:38 PM ET
    $BDSX
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by Biodesix Inc. (Amendment)

    SC 13D/A - BIODESIX INC (0001439725) (Subject)

    5/23/24 7:10:37 PM ET
    $BDSX
    Medical Specialities
    Health Care